Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of RP902 tablets for mild cognitive impairment due to Alzheimer's disease
CTR20261318Phase 2Active
- Sponsor
- Runjia Pharmaceutical
- Start
- Jul 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of RP902 in mild cognitive impairment due to Alzheimer's disease, sponsored by Runjia Pharmaceutical. Started Jul 2026; status: active.
02
Drugs
RP902
03
Conditions
mild cognitive impairment due to Alzheimer's disease
Beyond the preview
Go deeper on CTR20261318.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261318.